Investor Ideas #Potcasts
627, #Cannabis News and #Stocks on the Move- Interview with CEO of Juva Life
(CSE: $JUVA.C) (OTCQB: $JUVAF)
Delta, Kelowna, BC, March 11, 2022 (Investorideas.com Newswire),
investorideas.com, a global news
source covering leading sectors including marijuana and hemp stocks and its potcast site release today’s podcast edition of cannabis news and stocks to watch plus insight
from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2022/031122-StocksToWatch.mp3
Read this in full
at https://www.investorideas.com/news/2022/cannabis-potcasts/03111Interview-JUVA.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
Today’s podcast overview/transcript:
In today’s podcast
Investorideas interviews Doug Chloupek, CEO of Juva Life Inc. (CSE: JUVA) (OTCQB:JUVAF) a cannabis cultivation and life
sciences company aimed of unlocking the secret of pain management, where we
discussed the company’s recent filing of a patent application with the
United States Patent and Trademark Office (USPTO) on JUVA-041, a small molecule
isolated from the cannabis plant that has been identified by Juva’s in-house
research team, the potential applications of such small molecules, as well as
where the industry is heading with regards to cannabinoid based research.
When asked about
what helps differentiate Juva Life from other cannabinoid life sciences
companies Chloupek commented, “Juva is a life science research company with
heavy interest and focus on pharmaceutical new drug developments, specifically
with small molecules targeting inflammation and unlocking the mysteries of
cannabis. With that we have another arm of the company which really participates in the cannabis
sector, so cultivation, distribution and delivery, and that’s really what supplies
the revenue for the real fun of the company which is it’s life science
portion.”
Chloupek went on to
discuss his perspective on how the potential upside for the small molecules and
life sciences portion of Juva far outweighs the strictly cannabis side of the
industry saying, “what you have in the cannabis industry, with no disrespect to
the cannabis industry because that’s where I come and that’s been my livelihood
for over a decade, is you have thousands of companies and brands fighting for
peanuts. When you’re looking at the pharmaceutical side of the industry it is
almost largely untapped, besides a couple of multi-billion dollar acquisitions
which have occurred of the last 12 months, and every single one of them are
looking anxiously on the sidelines for how they can participate, but they
can’ts because of federal restrictions, how they can get in, but they can’t
because of regulatory burdens, and then you have Juva, threading a very
complicated process and pathway, creating a new way that you can achieve
similar end goals. Unequivocally the value is in the pharmaceutical drug
development, the API development.”
Juva currently has
two main small molecule patents in the works, JUVA-019 and JUVA-041. For
JUVA-019 the Company has filed a patent application and has conducted
preclinical research showing that the compound is effective as a stand-alone
compound in inhibiting inflammation by modulating certain biomarkers in the
body. Through its research division, Juva scientists have continuously been evaluating
an internally curated database of compounds found in the cannabis plant for
their therapeutic benefit, leading to the identification of the two proprietary
compounds: JUVA-019 and JUVA-041, which the Company has nominated as drug
candidates for further preclinical investigation.
Speaking in more
detail about the potential for these small molecules, Chloupek stated, “we have
spent many many years and a lot of research, and I’ve put some of the smartest
people in the world on a task, to understand the complexities of cannabis. How
do you do that? How do you understand this complex plant that has thousands of
different chemicals and identify down to what is the mode of action? We all
know about the entourage effect which is the synergistic use of cannabinoids,
terpenes and other chemical properties in cannabis which synergistically work
together to create an effect on the human body. The question can then be asked,
is there a particular single thing in the cannabis plant that we attribute as
the entourage effect, or is it really necessary to have all of these other
compounds synergistically working together? That's what distills down to the
question of JUVA-019 and JUVA-041, is they are single molecule compounds found
in cannabis, they are not terpenes, they are not cannabinoids they are not
flavonoids, but they have been shown to be the key to the mode of action that
regulates the pathways of inflammation in the human body found in cannabis.”
Chloupek continued,
“So I can tell you for a fact, and this will be a mind blower for many
listening, but THC and CBD, in relation to JUVA-041 and JUVA-019, hold little
to no therapeutic value on inflammation in the human body, there is no added
synergy, and for that matter combining THC or CBD or any other cannabinoids,
downregulate the effectiveness of JUVA-019 and JUVA-041 down to the level of
the respective cannabinoids. So they are exponentially more potent on their
own, they regulate the cytokine pathways, and we are moving them through
toxicology and safety through In Vivo right now.”
The company also recently announced the launch of the
Company’s Journal App, designed to help cannabis users and patients track their
consumption, and gain insight into how cannabis products affect their health
and wellness.
“We’re proud to be one of the first
and only companies to offer consumers a daily tracking solution that provides
them a closer look at how their cannabis use affects their personal health and
wellness,” said Doug Chloupek, CEO and Founder of Juva. “One of Juva’s primary
goals is to expand our industry’s knowledge of the medicinal effects of
cannabis from a scientific perspective. The Journal App provides a personal
tracking solution for our customers and it gives Juva information that
compliments the data we collect via our research registry.”
Choupek went on to discuss in more
detail some of the potential applications of JUVA-019 and JUVA-041 within the
medical community, how he sees Juva’s business model influencing the industry
as whole and what’s next on the horizon for Juva LIfe.
To find out more information about
Juva Life Inc. click here.
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com
website and that this podcast is not an endorsement to buy products or services
or securities. Investors are reminded all investment involves risk and possible
loss of investment.
To hear more
Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
The
Investorideas.com podcasts are also available on iTunes ( Apple Podcasts)
, Audible , Spotify, Tunein, Stitcher,
Spreaker.com, iHeartRadio , Google
Podcasts and most audio platforms available.
About Investorideas.com - News that Inspires Big
Investing Ideas
Investorideas.com
publishes breaking stock news, third party stock research , guest posts and
original articles and podcasts in
leading stock sectors. Learn about
investing in stocks and get investor
ideas in cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable
energy, gaming and more. Investor Idea’s original branded content includes
podcasts and columns : Crypto Corner , Play
by Play sports and stock news , Investor Ideas Potcasts
Cannabis News and Stocks on the Move podcast ,
Cleantech
and Climate Change , Exploring
Mining , Betting
on Gaming Stocks Podcast and the AI
Eye Podcast.
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers.
Contact management and IR of each company
directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our
other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to
regulations of each country. Please read Investorideas.com privacy
policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Contact Investorideas.com
800
665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
No comments:
Post a Comment